SGLT2 Inhibitor for Lupus Nephritis with CKD
SGLT2 Inhibitor in Lupus Nephritis Patients With Chronic Kidney Disease
Recruiting
Phase 2
Interventional Study
Lupus Nephritis
Chronic Kidney Diseases
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Trial phase
- Phase 2
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 150 (estimated)
- Sponsor
- The University of Hong Kong · Other
Who this trial is looking for
This trial is looking for patients with lupus nephritis and chronic kidney disease (CKD) to see how a medication called an SGLT2 inhibitor affects kidney health. Participants will be monitored for side effects and changes in their condition.
Are You a Good Fit for This Trial?
You may be able to join if
- I have been diagnosed with lupus nephritis
- I have chronic kidney disease
- I am stable with my disease
- I have been taking a stable dose of prednisolone
- I may also be taking MMF or AZA
You may not be able to join if
- I have been diagnosed with another type of kidney disease
- I have type 1 diabetes
- I am on dialysis or have end-stage kidney disease
- I have frequent urinary tract infections
- I have a history of ketoacidosis
Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
Lupus nephritis (LN) is a common manifestation in patients with systemic lupus erythematosus (SLE), and is an important cause of acute kidney injury and chronic kidney disease (CKD). Although the standard-of-care treatments for active severe LN are effective, a substantial proportion of LN patients still develop CKD and eventually end-stage kidney disease (ESKD).
Cardiovascular complications are …
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
1. Patients with biopsy-proven Class III or IV or V LN according to the ISN/RPS 2003 classification
2. Patients with CKD (eGFR 15-60mL/min)
3. Patients in quiescent disease (defined as SLEDAI score \<4 with no points in the renal domain)
4. Patients on a stable dose of prednisol…
Contacts